PURPOSE: To determine whether passive immunization with pneumolysin antiserum can reduce corneal damage associated with pneumococcal keratitis. METHODS: New Zealand White rabbits were intrastromally injected with Streptococcus pneumoniae and then passively immunized with control serum, antiserum against heat-inactivated pneumolysin (HI-PLY), or antiserum against cytotoxin-negative pneumolysin (psiPLY). Slit lamp examinations (SLEs) were performed at 24, 36, and 48 hours after infection. An additional four corneas from rabbits passively immunized with antiserum against psiPLY were examined up to 14 days after infection. Colony forming units (CFUs) were quantitated from corneas extracted at 20 and 48 hours after infection. Histopathology of rabbit eyes was performed at 48 hours after infection. RESULTS: SLE scores at 36 and 48 hours after infection were significantly lower in rabbits passively immunized with HI-PLY antiserum than in control rabbits (P < or = 0.043). SLE scores at 24, 36, and 48 hours after infection were significantly lower in rabbits passively immunized with psiPLY antiserum than in control rabbits (P < or = 0.010). The corneas of passively immunized rabbits that were examined up to 14 days after infection exhibited a sequential decrease in keratitis, with an SLE score average of 2.000 +/- 1.586 at 14 days. CFUs recovered from infected corneas were not significantly different between each experimental group and the respective control group at 20 or 48 hours after infection (P > or = 0.335). Histologic sections showed more corneal edema and polymorphonuclear leukocyte (PMN) infiltration in control rabbits compared with passively immunized rabbits. CONCLUSIONS: HI-PLY and psiPLY both elicit antibodies that provide passive protection against S. pneumoniae keratitis.
PURPOSE: To determine whether passive immunization with pneumolysin antiserum can reduce corneal damage associated with pneumococcal keratitis. METHODS: New Zealand White rabbits were intrastromally injected with Streptococcus pneumoniae and then passively immunized with control serum, antiserum against heat-inactivated pneumolysin (HI-PLY), or antiserum against cytotoxin-negative pneumolysin (psiPLY). Slit lamp examinations (SLEs) were performed at 24, 36, and 48 hours after infection. An additional four corneas from rabbits passively immunized with antiserum against psiPLY were examined up to 14 days after infection. Colony forming units (CFUs) were quantitated from corneas extracted at 20 and 48 hours after infection. Histopathology of rabbit eyes was performed at 48 hours after infection. RESULTS:SLE scores at 36 and 48 hours after infection were significantly lower in rabbits passively immunized with HI-PLY antiserum than in control rabbits (P < or = 0.043). SLE scores at 24, 36, and 48 hours after infection were significantly lower in rabbits passively immunized with psiPLY antiserum than in control rabbits (P < or = 0.010). The corneas of passively immunized rabbits that were examined up to 14 days after infection exhibited a sequential decrease in keratitis, with an SLE score average of 2.000 +/- 1.586 at 14 days. CFUs recovered from infected corneas were not significantly different between each experimental group and the respective control group at 20 or 48 hours after infection (P > or = 0.335). Histologic sections showed more corneal edema and polymorphonuclear leukocyte (PMN) infiltration in control rabbits compared with passively immunized rabbits. CONCLUSIONS: HI-PLY and psiPLY both elicit antibodies that provide passive protection against S. pneumoniae keratitis.
Authors: Lea-Ann S Kirkham; Alison R Kerr; Gill R Douce; Gavin K Paterson; Deborah A Dilts; Dai-Fang Liu; Tim J Mitchell Journal: Infect Immun Date: 2006-01 Impact factor: 3.441
Authors: C D Georgakopoulos; A M Exarchou; S P Gartaganis; F Kolonitsiou; E D Anastassiou; G Dimitracopoulos; A Hjerpe; A D Theocharis; N K Karamanos Journal: Curr Eye Res Date: 2006-02 Impact factor: 2.424
Authors: Julian M Reed; Richard J O'Callaghan; Dalia O Girgis; Clare C McCormick; Armando R Caballero; Mary E Marquart Journal: Invest Ophthalmol Vis Sci Date: 2005-02 Impact factor: 4.799
Authors: J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton Journal: Infect Immun Date: 1994-12 Impact factor: 3.441
Authors: M K Johnson; M C Callegan; L S Engel; R J O'Callaghan; J M Hill; J A Hobden; G J Boulnois; P W Andrew; T J Mitchell Journal: Curr Eye Res Date: 1995-04 Impact factor: 2.424
Authors: Melissa E Sanders; Erin W Norcross; Quincy C Moore; Jonathan Fratkin; Hilary Thompson; Mary E Marquart Journal: J Ocul Pharmacol Ther Date: 2010-10-29 Impact factor: 2.671
Authors: Robert M Q Shanks; Nicholas A Stella; Kristin M Hunt; Kimberly M Brothers; Liang Zhang; Patrick H Thibodeau Journal: Infect Immun Date: 2015-05-04 Impact factor: 3.441
Authors: Erin W Norcross; Melissa E Sanders; Quincy C Moore; Sidney D Taylor; Nathan A Tullos; Rhonda R Caston; Sherrina N Dixon; Moon H Nahm; Robert L Burton; Hilary Thompson; Larry S McDaniel; Mary E Marquart Journal: Invest Ophthalmol Vis Sci Date: 2011-11-29 Impact factor: 4.799
Authors: Erin W Norcross; Nathan A Tullos; Sidney D Taylor; Melissa E Sanders; Mary E Marquart Journal: Curr Eye Res Date: 2010-09 Impact factor: 2.424
Authors: Quincy C Moore; Clare C McCormick; Erin W Norcross; Chinwendu Onwubiko; Melissa E Sanders; Jonathan Fratkin; Larry S McDaniel; Richard J O'Callaghan; Mary E Marquart Journal: Ophthalmic Res Date: 2009-07-23 Impact factor: 2.892
Authors: Melissa E Sanders; Erin W Norcross; Quincy C Moore; Chinwendu Onwubiko; Lauren B King; Jonathan Fratkin; Mary E Marquart Journal: Clin Ophthalmol Date: 2008-12